Published in CNS Oncol on December 21, 2016
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science (2002) 5.08
Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet (2002) 5.06
Inflammation, a key event in cancer development. Mol Cancer Res (2006) 5.03
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst (2002) 4.97
Autoimmune T cell responses in the central nervous system. Nat Rev Immunol (2009) 4.73
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist (2007) 4.01
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet (2000) 3.98
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet (1994) 3.97
Mouse models of tumor development in neurofibromatosis type 1. Science (1999) 3.40
Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci (1999) 3.36
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet (1996) 3.08
Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med (1997) 3.04
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Mouse tumor model for neurofibromatosis type 1. Science (1999) 2.89
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med (1994) 2.81
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol (2007) 2.75
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A (1990) 2.52
Von Recklinghausen's disease: a clinicopathological study. Ann Surg (1972) 2.50
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood (2004) 2.42
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
Microglia function in brain tumors. J Neurosci Res (2005) 2.18
Basic principles of immunological surveillance of the normal central nervous system. Glia (2001) 2.13
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol (1998) 1.97
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol (2012) 1.95
Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet (1996) 1.93
Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med (2000) 1.90
Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell (2008) 1.86
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (2005) 1.85
Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol (2002) 1.85
Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest (2003) 1.85
Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet (2000) 1.84
Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med (1998) 1.82
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet (2007) 1.80
Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med (2000) 1.71
Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg (2011) 1.67
Immune surveillance in the central nervous system. Nat Neurosci (2012) 1.63
Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res (2011) 1.61
Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell (2000) 1.58
A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol (1993) 1.58
Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet (1997) 1.55
The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol (1993) 1.55
TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest (2012) 1.52
Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med (2001) 1.50
Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet (2006) 1.48
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer (2011) 1.36
Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem (2000) 1.36
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet (2014) 1.34
Dual biological effects of the cytokines interleukin-10 and interferon-γ. Cancer Immunol Immunother (2011) 1.34
Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol (2012) 1.33
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep (2009) 1.32
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol (2014) 1.28
Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood (2008) 1.28
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol (2012) 1.27
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One (2014) 1.26
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med (2004) 1.26
Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res (2008) 1.24
Malignant peripheral nerve sheath tumors. Oncologist (2014) 1.23
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun (2007) 1.20
Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet (2014) 1.19
Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res (2012) 1.19
Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol (2000) 1.18
The human mast cell: an overview. Methods Mol Biol (2006) 1.17
Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics (2011) 1.17
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther (2007) 1.15
Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol (2013) 1.14
Vascular endothelial growth factor stimulates Schwann cell invasion and neovascularization of acellular nerve grafts. Brain Res (1999) 1.13
An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res (2006) 1.08
Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology (2011) 1.08
Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol (2004) 1.06
Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology (2003) 1.05
Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases. Ann Rheum Dis (2012) 1.05
Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol (2012) 1.04
PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol (2009) 1.04
Revisiting the Mechanisms of CNS Immune Privilege. Trends Immunol (2015) 1.04
Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol (2012) 1.03
Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol (2004) 1.03
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer (2011) 1.02
Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci (Landmark Ed) (2011) 1.02
Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J Neuroimmunol (2010) 1.01
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer (2012) 0.98
Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation. Cancer Res (2011) 0.98
Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin Cancer Res (2004) 0.97
Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience (2010) 0.96
NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res (2013) 0.96